Role of alpha interferon in multiple myeloma

Blood Reviews

Volumn 11, Issue 4, 1997, Pages 191-200

  Joshua, D E ^a   MacCallum, S ^a   Gibson, J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERFERON ANTIBODY; MELPHALAN; PREDNISONE; PROTEIN BCL 2; RECOMBINANT ALPHA INTERFERON; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DEPRESSION; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; IMMUNOREGULATION; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MALAISE; META ANALYSIS; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROPATHY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA;

EID: 0031440369     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90019-9     Document Type: Article

References (50)

1. Isaacs A, Lindenmann J. Virus interference. The interferon. Proc R Soc B 1957; 147: 258.
2. Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H. Interferon therapy in myelomatosis. Lancet 1979; i: 245.
3. Reynold JEF (ed). Martindale: The Extra Pharmacopoeia. 31st Edition. London: Royal Pharmaceutical Society, 1996. 653-654.
4. Salmon SE, Durie BGM, Young Y et al. Effect of cloned leucocyte interferons in the human tumour stem cell assay. J Clin Oncol 1983; 1: 217.
5. Trotta PP. Preclinical biology of alpha interferons. Semin Oncol 1986; 13: 3.
6. 1 arrest in the inhibition of tumour cell growth by interferon. Proc Natl Acad Sci USA 1980; 77: 1471.
7. Revel M, Kimci A, Shulman L. Role of interferon induced enzymes in the antiviral and antimitogenic effects of interferon. Ann N Y Acad Sci 1980; 350: 459.
8. Samid D, Chang EH, Friedman RM. Development of a transformed phenotype induced by a human RAS oncogene is inhibited by interferon. Biochem Biophys Res Commun 1985; 126: 509.
9. Edwards BS, Hawkins MJ, Borden EC. Comparative in vivo and in vitro action of human NK cells by two recombinant A-interferons differing in antiviral activity. Cancer Res 1984; 44: 3135.
10. Brenning G. The in vitro effect of leucocyte alfa interferon on human myeloma cells in a semi-solid agar culture system. Scand J Haematol 1985; 35: 178.
11. Anthes JC, Zhan Z, Gilchrest H, Egan R, Siegel MI, Billah MM. Interferon-a down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem J 1995; 309: 175.
12. Tanaka, H, Tanabe O, Iwato K et al. Sensitive inhibitory effect of interferon alpha on M-protein secretion of human myeloma cells. Blood 1989; 74: 1718.
13. Millar BC, Bell JBG. 2′,5′-oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon a2b do not correlate with clinical response. Br J Cancer 1995; 72: 1525.
14. Millar BC, Bell JBG, Powles RL. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon a2b after intensive therapy. Br J Cancer 1996; 73: 236.
15. Cooper MR, Welander CE. Interferons in the treatment of multiple myeloma. Semin Oncol 1986; 13: 334.
16. Aapro MS, Alberts DS, Salmon SE. Interactions of human leucocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumours in clonogenic assay. Cancer Chemother Pharmacol 1983; 10: 161.
17. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenburger C, Longo DL. Resistance to recombinant interferon a2a in hairy cell leukaemia associated with neutralising anti-interferon antibodies. NEJM 1988; 318: 1409.
18. Trown PW, Dennin JR, Kramer MJ, Connell EV, Palleroni AV. Antibodies to human leucocyte interferon in cancer patients. Lancet 1983; ii: 81.
19. Bell JBG, Barfoot R, Iveson T, Powles RL, Millar BC. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon a2b. Br J Cancer 1994; 70: 646.
20. Cotter FE. The role of the bcl-2 gene in lymphoma Br J Haematol 1990; 75: 449.
21. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost E, Mellstedt H, Einhorn S. Response to interferon therapy in patients with multiple myeloma correlates with expression of the bcl-2 oncoprotein. Int J Cancer 1995; 63: 190.
22. Reynold JEF (ed). Martindale: The Extra Pharmacopoeia. 31st Edition. London: Royal Pharmaceutical Society, 1996. 653-654.
23. Cooper RM. Interferons in the management of multiple myeloma. Semin Oncol 1988; 15: 21-25.
24. Case DC, Sonneborn HL, Paul SC, Heibel J, Boyd MA, Shepp MA, Dorsk BM, Bonnem E. Phase II study of rDNA interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986; 70: 1251-1254.
25. Committee of the chronic leukaemia-myeloma task force. National Cancer Institute. Proposed guidelines for protocol studies. II Plasma cell myeloma. Cancer Chemother Rep 1973; 145.
26. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1994; 12; 2405-2414.
27. Ahre A, Bjorkholm M, Mellstedt H et al. Human leucocyte interferon and intermittent high dose melphalan-prednisone administration in the treatment of myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984; 68: 1331.
28. Ahre A, Bjorkholm M, Osterborg A et al. High doses of natural alpha interferon (alpha-IFN) in the treatment of multiple myeloma - a pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1988; 41: 123.
29. Oken MM, Kyle RA, Kay NE. Interferon in the treatment of refractory myeloma: an Eastern Cooperative Oncology Group study. Leuk Lymph 1990; 1: 95.
30. Cooper MR. Interferons in the management of multiple myeloma. Semin Oncol 1988; 15: 21.
31. Cooper MR. A review of the clinical studies of alpha-interferon in the management of multiple myeloma. Semin Oncol 1991; 5: 18.
32. Cooper RB, Dear K, McIntyre RO et al. A randomized trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a cancer and leukaemia group B study. J Clin Oncol 1993; 11: 155.
33. Oken MM, Kyle RA, Griepp PR et al. Complete remission (CR) induction with VBMCP + interferon (rIFNa2) in multiple myeloma. 3 year follow-up. Proc ASCO 1989; 8: 272 (abstract 1062).
34. Oken MM, Leong T, Kay NE, Griepp PR, van Ness B, Kyle RA. The effect of adding interferon (rIFNa2) or high dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase III trial. Blood 1995; 86 (Suppl 1): 441a.
35. Osterborg A, Bjorkholm M, Bjoeman M et al. Natural interferon-a in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stage II and III: a randomised study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428.
36. Casassus P, Pegourie-Bandelier B, Sadoun A et al, for KIF Trial. Randomized comparison of interferon-α with VMCP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multicentre trial. Blood 1995; 86 (Suppl 1): 441a.
37. Ludwig H, Cohen AM, Polliack A et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicentre randomised trials and summary of other studies. Ann Oncol 1995; 6: 467.
38. The Nordic myeloma study group. Interferon-a2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomised controlled trial. Ann Intern Med 1996; 124: 212.
39. Joshua DE, Penny R, Matthews JP et al. Australian leukaemia study group myeloma II: a randomised trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haem 1997; 97: 994.
40. Alexanian R, Balzerac C, Haut S. Remission maintenance therapy for multiple myeloma. Arch Intern Med 1972; 135: 147-152.
41. Mandelli F, Avvisati G, Amadori S et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430-1434.
42. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomised study. Br J Haematol 1995; 89: 561-568.
43. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
44. Attal M, Huguet F, Schalfier D et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79; 1130-1136.
45. Powles R, Raje N, Cunningham D et al. Maintenance therapy for remission in myeloma with Intron-A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 1995; 13: 114-117.
46. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85; 3077-3085.
47. Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Br J Haematol 1996; 92: 255-262.
48. Samson D, Volin L, Schanz U, Bosi A, Gahrton G. Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 1996; 17(5): 759-762.
49. Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Blood 1993; 82; 3211-3219.
50. Alexanian R, Barlogie B, Guterman J. Alpha-interferon combination therapy of resistant myeloma. Am J Clin Oncol 1991; 14: 188-192.